Interstitial cystitis - intravesical treatment

Almeida, Fernando G.; Batezini, Nelson; Simões, Ricardo Santos; Bernardo, Wanderley Marques

doi:10.1590/1806-9282.65.4.535

Cited by 2 publications

(3 citation statements)

References 38 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) медикаментозное лечение: приём трицикличных антидепрессантов (амитриптиллин) [36 -40], при тяжёлом болевом синдроме -per os парацетамол [41]. Внутрипузырная терапия включала инстилляции препаратов (лидокаин, гепарин, диметилсульфоксид) [42,43] либо в виде монотерапии, либо путём их чередования;…”

Section: материалы и методыunclassified

Autologous platelet-rich plasma for the treatment of interstitial cystitis/bladder pain syndrome in women: evaluation of clinical efficacy

Medvedev,

Lepetunov,

Kogan

2023

Vestn. Urol.

View full text Add to dashboard Cite

Introduction. The pathogenetic theory of interstitial cystitis/bladder pain syndrome (IC / BPS) development declares that due to vascular changes and trophic disorders in the bladder wall, a complex of dystrophic, necrobiotic and sclerotic processes develops, involving all layers of the bladder wall with the subsequent development of fibrosis. Therapy of moderate-to-severe symptoms of IC/BPS that recommended in EAU guidelines is not so effective.Objective. To evaluate the results of intradetrusor autologous platelet-rich plasma (PRP) injections in female IC / BPS-patients.Matherials & methods. A single-centre controlled randomized prospective trial that includes 85 women from 20 to 79 years old and with average disease duration of 4.8 ± 2.1 years. They were divided into two groups: group 1 — 35 patients were treated with total of five cystoscopies and hydrodistension, each once in two weeks for 10 weeks; group 2 — 50 patients were treated with total of 5 intradetrusor PRP-injection (mean platelet concentration was 982 х 103/l) into 20 – 22 points, each once in two weeks. We assessed pain (VAS-scale), urgency and frequency (PUF-scale, IUS-scale), bladder urinary, Global Response Assessment (GRA), bladder diary and bladder capacity before treatment, after one and 12 months.Results. Conventional IC/BPS therapy leads to a significant reduction in symptoms one month after its completion, and a similar pattern of symptoms and signs is observed in the PRP-treatment group. However, in group 1, negative dynamics is further determined up to 12 months, but the indicators do not reach the initial values. In contrast, in group 2, we found stabilisation of pain severity and improvement of all other symptoms and signs by 12 months compared to baseline and one month after the completion of PRP-therapy.Conclusion. The developed method of PRP-therapy of IC/BPS has high efficacy not only at the treatment completion, but also at monitoring of patients for 24 months. PRP-therapy combined with classical treatment will probably have a higher level of efficacy both in terms of symptoms and signs of the disease over a long-term monitoring.

show abstract

Section: материалы и методыunclassified

Autologous platelet-rich plasma for the treatment of interstitial cystitis/bladder pain syndrome in women: evaluation of clinical efficacy

Medvedev,

Lepetunov,

Kogan

2023

Vestn. Urol.

View full text Add to dashboard Cite

show abstract

“…To reduce the loss of impermeability of the urothelium, glycosaminoglycan-based treatments have been used (mainly pentosan polysulphate). However, treatment times (over 6 months) and the high relapse rate (23% at 1 year) are significant limitations [ 85 , 86 , 87 , 88 , 89 , 90 ]. To reduce inflammation, drugs such as hydroxyzine, cimetidine and corticosteroids have been used.…”

Section: Molecular Mechanisms In Cystitismentioning

confidence: 99%

“…DMSO has an analgesic effect on the afferent nerves. Despite a high level of efficacy (between 61 and 95%) [ 103 ], its limitations are an increase in urothelium lesions and increased fibrosis [ 85 , 87 , 88 , 91 , 103 , 104 , 105 ]. Tricyclic antidepressants (amitriptyline) have an efficacy rate of 50% to 66%, but decrease patients’ quality of life (causing drowsiness and nausea) [ 106 ].…”

Section: Molecular Mechanisms In Cystitismentioning

confidence: 99%

Molecular Mechanisms and Key Processes in Interstitial, Hemorrhagic and Radiation Cystitis

Brossard

Lefranc

Pouliet

et al. 2022

Biology

View full text Add to dashboard Cite

Cystitis is a bladder disease with a high rate of prevalence in the world population. This report focuses on Interstitial Cystitis (IC), Hemorrhagic Cystitis (HC) and Chronic Radiation Cystitis. These pathologies have different etiologies, but they share common symptoms, for instance, pain, bleeding, and a contracted bladder. Overall, treatments are quite similar for abacterial cystitis, and include bladder epithelium protective or anti-inflammatory agents, alleviating pain and reducing bleeding. This review summarizes the mechanisms that the pathologies have in common, for instance, bladder dysfunction and inflammation. Conversely, some mechanisms have been described as present in only one pathology, such as neural regulation. Based on these specificities, we propose identifying a mechanism that could be common to all the above-mentioned pathologies.

show abstract

Interstitial cystitis - intravesical treatment

Abstract: The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.

Cited by 2 publications

References 38 publications

Autologous platelet-rich plasma for the treatment of interstitial cystitis/bladder pain syndrome in women: evaluation of clinical efficacy

Autologous platelet-rich plasma for the treatment of interstitial cystitis/bladder pain syndrome in women: evaluation of clinical efficacy

Molecular Mechanisms and Key Processes in Interstitial, Hemorrhagic and Radiation Cystitis

Contact Info

Product

Resources

About